As of May 2024, about 22% of adults who had been told by a doctor that they are overweight or obese said they had ever taken a GLP-1 drug, according to a KFF poll
Ozempic and GLP-1 Drugs Detail Expanded Use of GLP-1 Antogist Dr Caroline Messer, an endocrinologist is interviewed by the Economist Podcast and says that the anti-inflammatory action of GLP-1s has promise in the following areas
Research has documented reduced fat mass, decreased adipocyte size, and shifts in adipose tissue gene expression patterns toward fat-mobilizing rather than fat-storing phenotypes
Statements Author contributions YY and YL conceived the study and designed the contents
Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial
At its highest dose, 36 mg, participants in a phase 3 trial lost an average of 12.4 percent of their starting weight over 72 weeks